ConductScience.org, home

Paper36136306

Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.

Sun L and 9 others. JAMA Otolaryngol Head Neck Surg, 2022. Cited by 35 papers, by iCite.

Cite this record

ConductScience Library. Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer. Papers, record 36136306. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36136306

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.
PubMed
Journal
JAMA Otolaryngol Head Neck Surg
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
35
iCite
Relative citation ratio, by iCite
2.25
iCite
Revised in PubMed
2023-09-23
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sun LLova
2Candelieri-Surette DDanielle
3Anglin-Foote TTori
4Lynch JAJulie A
5Maxwell KNKara N
6D'Avella CChristopher
7Singh AAditi
8Aakhus EErin
9Cohen RBRoger B
10Brody RMRobert M

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Squamous CellMajor topic
Head and Neck NeoplasmsMajor topic
Male
Humans
Middle Aged
Cetuximab
Carboplatin
Cisplatin
Squamous Cell Carcinoma of Head and Neck
Cohort Studies
Chemoradiotherapy
Antineoplastic Combined Chemotherapy Protocols

Source PubMed

Download CSV of topics

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in36480179Problems With Interpreting Treatment Effects in Observational Competing Risks Data.https://conductscience.org/library/papers/36480179PubMed
Comment in36480187Problems With Interpreting Treatment Effects in Observational Competing Risks Data-Reply.https://conductscience.org/library/papers/36480187PubMed

Download CSV of comments and corrections

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134098030Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study.Int J Radiat Oncol Biol Phys2021https://conductscience.org/library/papers/34098030PubMed
225936651Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer.Oral Oncol2015https://conductscience.org/library/papers/25936651PubMed
321225900Multiple imputation using chained equations: Issues and guidance for practice.Stat Med2011https://conductscience.org/library/papers/21225900PubMed
425366680
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.
J Clin Oncol2014https://conductscience.org/library/papers/25366680PubMed
522261362
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Lancet Oncol2012https://conductscience.org/library/papers/22261362PubMed
630449625Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.Lancet2019https://conductscience.org/library/papers/30449625PubMed
721969503Human papillomavirus and rising oropharyngeal cancer incidence in the United States.J Clin Oncol2011https://conductscience.org/library/papers/21969503PubMed
820530316Human papillomavirus and survival of patients with oropharyngeal cancer.N Engl J Med2010https://conductscience.org/library/papers/20530316PubMed
925492084Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.Clin Cancer Res2015https://conductscience.org/library/papers/25492084PubMed
1019634161Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.Cancer2009https://conductscience.org/library/papers/19634161PubMed
1126232905Cardiovascular Disease Risk Factors Among Male Veterans, U.S., 2009-2012.Am J Prev Med2016https://conductscience.org/library/papers/26232905PubMed
1225132089Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC).Oral Oncol2014https://conductscience.org/library/papers/25132089PubMed
1316467544Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N Engl J Med2006https://conductscience.org/library/papers/16467544PubMed
1431609479Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.Int J Cancer2020https://conductscience.org/library/papers/31609479PubMed
1521947123Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.Strahlenther Onkol2011https://conductscience.org/library/papers/21947123PubMed
1626270931Characteristics of Human Papillomavirus-Associated Head and Neck Cancers in a Veteran Population.JAMA Otolaryngol Head Neck Surg2015https://conductscience.org/library/papers/26270931PubMed
1725013689Veterans and risk of heart disease in the United States: a cohort with 20 years of follow up.Int J Prev Med2014https://conductscience.org/library/papers/25013689PubMed
1822550060Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy.Oncologist2012https://conductscience.org/library/papers/22550060PubMed
1933052757ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer.J Clin Oncol2021https://conductscience.org/library/papers/33052757PubMed
2032073648A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.Cancer2020https://conductscience.org/library/papers/32073648PubMed

See all 28 referencesDownload CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.

PMIDTitleJournalYearIn PapersSource
42532979The Impact of the G8 Score on Survival Outcomes in Patients With Head and Neck Cancer Undergoing Concurrent Radiotherapy With Cetuximab due to Contraindications With Cisplatin.Cancer Med2026https://conductscience.org/library/papers/42532979PubMed
42322527Cancer-associated fibroblasts as a target in head and neck squamous cell carcinoma: bridging mechanisms to therapy with drugs, adjuvants, and nanotechnology.Discov Oncol2026https://conductscience.org/library/papers/42322527PubMed
41465310Platinum Meets Pyridine: Affinity Studies of Pyridinecarboxylic Acids and Nicotinamide for Platinum-Based Drugs.Int J Mol Sci2025https://conductscience.org/library/papers/41465310PubMed
41344314Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience.J Natl Cancer Inst2026https://conductscience.org/library/papers/41344314PubMed
41228343Retrospective Trial on Cetuximab Plus Radiotherapy in Elderly Patients with Head and Neck Squamous Cell Cancer.Cancers (Basel)2025https://conductscience.org/library/papers/41228343PubMed
41212257Otoprotective measures for cisplatin-based chemoradiotherapy-induced toxicity in patients with head and neck cancer: a systematic review and meta-analysis.Support Care Cancer2025https://conductscience.org/library/papers/41212257PubMed
40763210Tumor-infiltrating nociceptor neurons promote immunosuppression.Sci Signal2025https://conductscience.org/library/papers/40763210PubMed
40353748Early-Phase Trial of IAP Antagonist Tolinapant and Definitive Radiation in Cisplatin-Ineligible Patients with Advanced Head and Neck Cancer.Clin Cancer Res2025https://conductscience.org/library/papers/40353748PubMed
40323514Concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma: survival analysis based on 2-year follow-up data.Int J Clin Oncol2025https://conductscience.org/library/papers/40323514PubMed
39641447Concurrent immunotherapy and radiation in cisplatin-ineligible patients with HNSCC: a systematic review & meta-analysis.Immunotherapy2024https://conductscience.org/library/papers/39641447PubMed
39551064
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
Lancet Oncol2024https://conductscience.org/library/papers/39551064PubMed
39093329Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review.J Cancer Res Clin Oncol2024https://conductscience.org/library/papers/39093329PubMed
38992100Gemcitabine as chemotherapy of head and neck cancer in Fanconi anemia patients.Oncogenesis2024https://conductscience.org/library/papers/38992100PubMed
38727853Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.Int J Clin Oncol2024https://conductscience.org/library/papers/38727853PubMed
37843751Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.Int J Clin Oncol2024https://conductscience.org/library/papers/37843751PubMed
37831345Study of anticancer effects of platinum levetiracetam and levetiracetam via cancer biomarkers genes expression on HepG2 cell line.Mol Biol Rep2023https://conductscience.org/library/papers/37831345PubMed
37664029Real-world study of patients with locally advanced HNSCC in the community oncology setting.Front Oncol2023https://conductscience.org/library/papers/37664029PubMed
37576899De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: evolving paradigms and future strategies.Front Oncol2023https://conductscience.org/library/papers/37576899PubMed
37444388Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN).Cancers (Basel)2023https://conductscience.org/library/papers/37444388PubMed
37439286Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer.Head Neck2023https://conductscience.org/library/papers/37439286PubMed

See all 22 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36136306

GET https://conductscience.org/api/papers/v1/36136306/references?page=2